Compare MYO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | HOWL |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 30.7M |
| IPO Year | 2017 | 2021 |
| Metric | MYO | HOWL |
|---|---|---|
| Price | $1.04 | $0.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $7.67 | $5.00 |
| AVG Volume (30 Days) | 335.5K | ★ 579.5K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.61 | $0.40 |
| 52 Week High | $3.22 | $2.23 |
| Indicator | MYO | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 29.99 |
| Support Level | $0.90 | N/A |
| Resistance Level | $1.10 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 81.85 | 12.10 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.